The present invention relates to compounds according to formula 1,
which exhibit cytotoxic activity. The compounds may be used in the treatment of cancer.
本发明涉及符合式1的化合物,具有细胞毒活性。这些化合物可用于治疗癌症。
[EN] 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES<br/>[FR] DÉRIVÉS DE 2,3-DIHYDROBENZO[1,4] DIOXIN-2-YLMÉTHYLE UTILISÉS EN TANT QU'ANTAGONISTES DES ALPHA2C POUR TRAITER DES MALADIES DES SYSTÈMES NERVEUX PÉRIPHÉRIQUE ET CENTRAL
申请人:ORION CORP
公开号:WO2009013390A1
公开(公告)日:2009-01-29
Compounds of formula (I), wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity and are thus useful for the treatment of diseases and conditions of the peripheric system and the central nervous system (CNS).
[EN] SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS<br/>[FR] COMPOSÉS CARBAMATE SUBSTITUÉS ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DU CANAL POTENTIEL RÉCEPTEUR TRANSITOIRE (TRP)
申请人:HOFFMANN LA ROCHE
公开号:WO2014060341A1
公开(公告)日:2014-04-24
The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.
2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES
申请人:Din Belle David
公开号:US20120035210A9
公开(公告)日:2012-02-09
Compounds of formula I
wherein X, Z, R
1
-R
4
, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.
Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors
申请人:Amgen Inc.
公开号:US20130150339A1
公开(公告)日:2013-06-13
The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7.
The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.